Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

Completed

• Conditions: Non-Hodgkin T-cell Lymphoma
• Interventions: Other: Prospective Registry

• Registration Number: NCT02691351
• Lead Sponsor: Samsung Medical Center

Brief Summary

The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2016-02-17
• Study First Submitted QC: 2016-02-21
• Study First Posted: 2016-02-25
• Study Start: 2016-03
• Primary Completion: 2020-07
• Status Verified: 2020-09
• Study Completion: 2020-09
• Last Update Submitted: 2020-09-08
• Last Update Posted: 2020-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008
• Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients
• Age ≥19 years
• Written informed consent

Read More

Exclusion Criteria

• Hodgkin lymphoma
• non-Hodgkin B-cell lymphoma
• Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia
• Not understanding informed consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
non-Hodgkin T-cell Lymphoma	Prospective Registry	-

Primary Outcome Measures

Name	Time	Method
Overall survival	5 years

Secondary Outcome Measures

Name	Time	Method
Overall response rate to primary treatment and salvage treatment	5 years
Progression-free survival	5 years

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of